PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY 971.90
-1.80 (-0.18%)
Aug 6, 2026, 9:54 AM JST
PeptiDream Revenue
PeptiDream had revenue of 4.76B JPY in the quarter ending March 31, 2026, with 12.56% growth. This brings the company's revenue in the last twelve months to 19.05B, down -59.19% year-over-year. In the year 2025, PeptiDream had annual revenue of 18.52B, down -60.32%.
Revenue (ttm)
19.05B
Revenue Growth
-59.19%
P/S Ratio
6.57
Revenue / Employee
25.57M
Employees
745
Market Cap
125.11B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.52B | -28.16B | -60.32% |
| Dec 31, 2024 | 46.68B | 17.96B | 62.57% |
| Dec 31, 2023 | 28.71B | 1.86B | 6.93% |
| Dec 31, 2022 | 26.85B | 17.49B | 186.70% |
| Dec 31, 2021 | 9.37B | -2.31B | -19.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 34.23B |
| GNI Group | 27.05B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.52B |
| AnGes | 908.00M |
| Cuorips | 212.00M |
| Healios K.K. | 74.00M |
| Renascience | 68.00M |
PeptiDream News
- 4 weeks ago - PeptiDream appoints three new executive vice presidents - TheFly
- 7 weeks ago - PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer - Business Wire
- 7 weeks ago - PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - Business Wire
- 7 weeks ago - Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire
- 2 months ago - PeptiDream Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 months ago - PeptiDream Quarterly report: Q1 2026 - Filings
- 3 months ago - PeptiDream announces initiation of Phase 1 clinical trial of AK1940 - TheFly
- 3 months ago - PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner - Business Wire